| Filed On | Filing |
|---|---|
| 23 Jul 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more
Section 1.1: Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors (the “Board”) of Elevation Oncology, Inc. (the “Co... |
| 02 Jul 2025 |
8-K: Termination of a Material Definitive Agreement
On June 26, 2025 (the “Effective Date”), Elevation Oncology, Inc. (the “Company”) entered into a Mutual Release and Termination Agreement (the “Termination Agreement”) with CSPC Megalith Biopharmaceutical Co., Ltd. (“CSPC”), pursuant to ... |
| 09 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +2 more
This AGREEMENT AND PLAN OF MERGER, dated as of June 8, 2025 (this “Agreement” and, such date, the “Agreement Date”), by and among Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), Concentra Merger Sub VI, Inc.,... |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- |
| 05 May 2025 |
8-K: Triggering Events That Accelerate a Financial Obligation
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. |
| 04 Apr 2025 |
8-K: Triggering Events That Accelerate a Financial Obligation
Triggering Events That Accelerate or Increases a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. |
| 01 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 20 Mar 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- |
| 19 Mar 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements |
| 31 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 Jan 2025 |
8-K: Other Events
On January 13, 2025, Elevation Oncology, Inc. (the “Company”) issued a press release announcing program updates and upcoming milestones. The Company announced that, with respect to its ongoing Phase 1 clinical trial of EO-3021, a Claudin... |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- |
| 20 Sep 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 06 Aug 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- |
| 14 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 13, 2024, Elevation Oncology, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for each proposal considered at the Annual Meeting are set forth below. For more inf... |
| 02 May 2024 |
8-K: Results of Operations and Financial Condition
-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- |
| 05 Apr 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 06 Mar 2024 |
8-K: Results of Operations and Financial Condition
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements |
| 23 Jan 2024 |
8-K: Other Events
As previously disclosed, on September 19, 2023, Elevation Oncology, Inc. (the “Company”) received notice from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price fo... |
Loading...